A recent phase II clinical trial (Reducing Residual Albuminuria in Subjects with Diabetes and Nephropathy with AtRasentan trial and an identical trial in Japan (RADAR/JAPAN)) showed that the endothelin A receptor antagonist atrasentan lowers albuminuria, blood pressure, cholesterol, hemoglobin, and increases body weight in patients with type 2 diabetes and nephropathy. We previously developed an algorithm, the Parameter Response Efficacy (PRE) score, which translates short-term drug effects into predictions of long-term effects on clinical outcomes.
Prediction of the effect of atrasentan on renal and heart failure outcomes based on short-term changes in multiple risk markers / B. Schievink, D. de Zeeuw, P.A. Smink, D. Andress, J.J. Brennan, B. Coll, R. Correa Rotter, F.F. Hou, D. Kohan, D.W. Kitzman, H. Makino, H. Parving, V. Perkovic, G. Remuzzi, S. Tobe, R. Toto, J. Hoekman, H.J. Lambers Heerspink. - In: EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY. - ISSN 2047-4873. - 23:7(2015), pp. 758-768. [10.1177/2047487315598709]
Prediction of the effect of atrasentan on renal and heart failure outcomes based on short-term changes in multiple risk markers
G. Remuzzi;
2015
Abstract
A recent phase II clinical trial (Reducing Residual Albuminuria in Subjects with Diabetes and Nephropathy with AtRasentan trial and an identical trial in Japan (RADAR/JAPAN)) showed that the endothelin A receptor antagonist atrasentan lowers albuminuria, blood pressure, cholesterol, hemoglobin, and increases body weight in patients with type 2 diabetes and nephropathy. We previously developed an algorithm, the Parameter Response Efficacy (PRE) score, which translates short-term drug effects into predictions of long-term effects on clinical outcomes.
| File | Dimensione | Formato | |
|---|---|---|---|
|
Remuzzi_PreventiveCardiology_PredictionAtrasentan_2016.pdf
accesso riservato
Tipologia:
Publisher's version/PDF
Dimensione
769.78 kB
Formato
Adobe PDF
|
769.78 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
